258 - Exploratory Analysis of Plasma Protein Abundance Kinetics from I-SABR, A Randomized Phase II Trial of Stereotactic Ablative Radiotherapy with or without Nivolumab in Stage I-IIA or Recurrent Non-Small
1044 - TEAMRO: Final Analysis of TEAMRO (TEAching Mentorship in Radiation Oncology), A Multicenter Prospective Phase 2 Intervention Study on Teaching Mentorship Skills to Resident Physicians Working with Med
Location: Room 158
Presenter: Anurag Saraf, MD – Brigham and Women's Hospital/Dana-Farber
8:20 AM - 8:25 AM ET
1045 - Patterns of Contouring Mistakes in the Novice Resident: A Qualitative Analysis to Guide Future Educational Efforts
1047 - Optimizing Leadership Development Strategies for Enhanced Leader and Team Impact
Location: Room 158
Presenter: Amanda Woods, PhD – The University of Texas MD Anderson Cancer Center
8:35 AM - 8:55 AM ET
Questions and Answers
Location: Room 158
8:55 AM - 9:00 AM ET
Closing
Location: Room 158
8:00 AM - 8:05 AM ET
Introduction
Location: Room 140
8:05 AM - 8:10 AM ET
1037 - ctDNA Predicts Pain Response in a Multi-Institutional Phase II Trial of Palliative Radiation, Palbociclib and Hormone Therapy in Metastatic Breast Cancer
1038 - Final Report of a Phase I/II Study of BMS-986156 (Glucocorticoid-Induced TNFR-Related Gene [GITR] Agonist) with Ipilimumab or Nivolumab with/without Stereotactic Ablative Radiotherapy in Patients with
Location: Room 140
Presenter: Xinyan Xu, MD – MD Anderson Cancer Center
8:20 AM - 8:25 AM ET
1039 - Identifying Patients with Bone Metastases at Highest Risk of Skeletal-Related Events and Understanding Underuse of Bone Modifying Agents: A Retrospective Analysis
1040 - Development of Nomograms to Predict Polymetastatic Progression Free Survival and Overall Survival in Patients Treated with Stereotactic Ablative Radiotherapy for Oligometastatic or Oligoprogressive Ca
Location: Room 140
Presenter: Subhadip Das, MD – BC Cancer Surrey and University of British Columbia
8:30 AM - 8:35 AM ET
1041 - Progress in Shortening Treatment Courses for Bone Metastases in a Statewide Quality Consortium
1031 - Using Virtual Monoenergetic Images and Electron Density (Rho) Images from Photon-Counting CT (PCCT) for Radiation Therapy (RT) Dose Calculation: A Comparison Study
Location: Room 152
Presenter: Xin Wu, MS – Duke University Medical Center
8:15 AM - 8:20 AM ET
1032 - Comparison of Enhanced Cone-Beam CT Using Next Generation Reconstruction with Deep Learning-Based Synthetic CT for Adaptive Radiotherapy in Pelvic Cancers
277 - The Association of Left Anterior Descending Coronary Artery Radiation Dose with Major Adverse Cardiac Events Following Modern Breast Radiotherapy
279 - Safety and Efficacy of Combined Trastuzumab-Deruxtecan and Concurrent Radiation Therapy in Breast Cancer: The TENDANCE Multicentric French Study (Trastuzumab-Deruxtecan and Concurrent Radiation Therap
Location: Room 207
Presenter: Kamel Debbi, MD – Henri Mondor University Hospital and Faculte de Medecin de Creteil Paris XII
1:15 PM - 1:25 PM ET
280 - Characterization of Skin Microbiome Profile before and during Radiation Therapy and Its Correlation to the Occurrence and Severity of Radiation Dermatitis
281 - A Phase I/II Trial of Spectrophotometric Skin Changes during and after Radiotherapy and Correlation with Radiation-Induced Skin Toxicity in Breast Cancer Patients with Skin of Color
Location: Room 207
Presenter: Juhi Purswani, MD – New York University School of Medicine
1:35 PM - 1:45 PM ET
282 - Analysis of Rib Fracture Risk after Breast Radiation with Various Dose Fractionations
Location: Room 207
Presenter: Jackson Howell, MD – University of Utah Huntsman Cancer Institute
283 - Measuring the Integration of Stereotactic Ablative Radiotherapy plus Surgery for Early-Stage Non-Small Cell Lung Cancer (MISSILE): Long-Term Clinical Outcomes
Location: Room 147
Presenter: Vivian Tan, MD – London Health Sciences Centre
12:55 PM - 1:05 PM ET
284 - A Phase II Randomized Trial of Radical Resection vs. Stereotactic Body Radiation Therapy (SBRT) in Patients with Operable Stage I Non-Small Cell Lung Cancer (NSCLC): Final Report Of RTOG-F3502
286 - Dosimetric Outcomes of SBRT to Ultracentral Lung Tumors: Lessons from the SUNSET Trial
Location: Room 147
Presenter: Rohan Salunkhe, MD, MBBS – Princess Margaret Cancer Center, University Health Network
1:25 PM - 1:35 PM ET
287 - Accelerated Hypofractionated Chemoradiation Followed by Stereotactic Ablative Radiotherapy Boost for Locally Advanced, Unresectable Non-Small Cell Lung Cancer: Final Results from a Nonrandomized Contr
288 - A Phase I Study of Cyclical Hypofractionated Palliative Radiation (Quad Shot) for Lung Tumors in Patients with Stage IV Non-Small Cell Lung Cancer (NSCLC): Results from the PROMISE 006 Trial
Location: Room 147
Presenter: Helen Zhang, MD – Memorial Sloan Kettering Cancer Center
272 - Impact of Organ-at-Risk (OAR) Radiation Dosimetry on Acute and Late Toxicity after Prostate Stereotactic Body Radiation Therapy (SBRT): A Post-Hoc Analysis of a Phase III Randomized Clinical Trial of
273 - Redefining Breast Cancer Tumor Size Classification through Big Data Analytics: A New Approach to Enhancing Prognostic Accuracy and Personalized Treatment
Location: Room 152
Presenter: Bin Feng, MS, BS – Chongqing University Cancer Hospital
1:25 PM - 1:35 PM ET
274 - Evaluation of Immune System Plasticity with a Multi-Compartment Model of Immuno-Positron Emission Tomography
1048 - Bridging Prediction and Causality: Deciphering Clinical Outcomes in Locally Advanced Non-Small Cell Lung Cancer Treated with Chemoradiation via Multitask Machine Learning and Causal Inference of Proto
1052 - Predicting Pulmonary Toxicity in Lung Cancer Patients with Interstitial Lung Disease Receiving SABR Using Machine Learning: A Secondary Analysis of ASPIRE-ILD
1067 - Evaluation of Genomic and Pathologic Features Associated with Outcomes among Patients with Sentinel Lymph Node-Positive Melanoma in the Contemporary Era
1069 - Preoperative Hypofractionated Radiotherapy with Locoregional Hyperthermia in Recurrent and Radiation-Associated Sarcomas: Final Results of a Phase 2 Clinical Trial
Location: Room 151
Presenter: Mateusz SpaÅ‚ek, MD, DSc, PhD, MBA – Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie – Panstwowy Instytut Badawczy w Warszawie
2:55 PM - 3:00 PM ET
1070 - Long-Term Outcomes following Proton-Based Radiation Therapy for Pediatric Chordomas and Chondrosarcomas of the Mobile Spine and the Sacrum
1065 - Use of the 40-Gene Expression Profile (40-GEP) Test to Identify Immune Suppressed Patients with Brigham and Womens Hospital (BWH) T1-T2a Cutaneous Squamous Cell Carcinoma (cSCC) at Higher Risk of Meta
304 - Phase II Trial of Organ Preservation Program Using Short-Course Radiation and Folfoxiri for Rectal Cancer (SHORT-FOX): Clinical Response Outcomes
Discussant: Emma Holliday, MD – The University of Texas MD Anderson Cancer Center
2:30 PM - 2:40 PM ET
296 - Induction Chemotherapy plus Concurrent Chemoradiotherapy vs. Concurrent Chemoradiotherapy Alone in High-Risk Locally Advanced Cervical Carcinoma: A Phase 2, Multicenter, Randomized Controlled Trial
Location: Room 209
Presenter: Hua Yang, MD – The First Affiliated Hospital of Air Force Medical University
2:40 PM - 2:50 PM ET
297 - Comparison of Image-Guided Intensity Modulated Radiotherapy (IG-IMRT) vs. Conventional Radiotherapy (4FRT) for Locoregionally Advanced Cervical Cancer on the NRG GY006 Trial
298 - IMMUNOCERV Phase II Trial Combining the HPV-Specific T Cell Immunotherapy PDS0101 with Chemoradiation for Treatment of Locally Advanced Cervical Cancer
300 - Comparison of Docetaxel and Cisplatin Concurrent and Short-Course Adjuvant Chemotherapy with Cisplatin Concurrent Chemotherapy in Radiotherapy for Locally Advanced Cervical Cancer: A Phase III Multice
LBA08 - Outcomes and Immune Responses from INNATE: A Randomized Phase II Trial of Sotigalimab Immunotherapy during Neoadjuvant Therapy of Rectal Cancer
LBA11 - A Phase II Single Arm Trial of Elective Volume Adjusted De-Escalation Radiotherapy (EVADER) in Patients with Low-risk HPV-related Oropharyngeal Squamous Cell Carcinoma
LBA12 - Radiotherapy Target Volume Delineation Based on Post-Induction Chemotherapy Gross Tumor Volume vs. Pre-induction Volume for Locoregionally Advanced Nasopharyngeal Carcinoma: An Open-Label, Non-Inferio
LBA13 - Safety Profile of Durvalumab (D) as Consolidation Treatment (tx) in Limited-Stage Small-Cell Lung Cancer (LS-SCLC) in ADRIATIC: Focus on Pneumonitis and Immune-Mediated Adverse Events (imAEs)
LBA14 - Neurocognitive Outcome of Conformal Whole Brain Radiotherapy with Bilateral or Unilateral Hippocampal Avoidance Plus Memantine for Brain Metastases: A Phase II Single Blind Randomized Trial
308 - Phase I/II Prospective Dose Escalation Trial with Proton-Based Radiation Therapy for Chordomas and Chondrosarcomas of the Skull Base and Cervical Spine: Long-Term Results from Proton Radiation Oncolog
317 - Magnetic Resonance Imaging-Guided vs. Computed Tomography-Guided Stereotactic Body Radiotherapy for Prostate Cancer: 2-Year Outcomes from the MIRAGE Randomized Clinical Trial
318 - Volumetric Changes and Acute Toxicity with 68Ga Prostate-Specific Membrane Antigen vs 18F-Fluciclovine PET/CT Guided Post-Prostatectomy Radiation: Final Analysis of a Randomized Trial
319 - Dose Escalated Pelvic Lymph Node Intensity Modulated Radiation Therapy (IMRT) with a Simultaneous Hypofractionated Boost to the Prostate for NCCN Very-High Risk Adenocarcinoma of the Prostate, a Prosp
Location: Room 202
Presenter: William Hall, MD – Medical College of Wisconsin (MCW)
4:30 PM - 4:40 PM ET
320 - Initial Results of a Multi-Institutional Phase 1/2 Trial of Focal Dose-Escalated Salvage High Dose Rate Brachytherapy for Radiorecurrent Prostate Cancer (F-SHARP)
321 - Focal MR-Guided HDR Brachytherapy Boost Combined with SBRT for Localized Prostate Cancer
Location: Room 202
Presenter: Carlton Johnny, MD – Princess Margaret Cancer Center, University Health Network
4:50 PM - 5:00 PM ET
322 - Stereotactic Body Radiotherapy (SBRT) vs. Conventional Fractionation External Beam Radiotherapy (EBRT) Boost for Unfavorable Intermediate and High-Risk Prostate Cancer; Early Results of PBS: A Phase I
312 - Phase II Study of Radiation Volume and Dose De-Intensification Following Tors and Neck Dissection for p16+ Oropharyngeal Squamous Cell Carcinoma - Long-Term Results of Expanded Cohort
Location: Room 145
Presenter: John Lukens, MD – Hospital of the University of Pennsylvania
4:10 PM - 4:20 PM ET
313 - Quality of Life (QOL) of Patients with Human Papillomavirus (HPV)-Associated Oropharyngeal Squamous Cell Carcinoma (OPSCC) in NRG-HN002
315 - HPV-Seq is Prognostic in p16-Positive Oropharyngeal Cancer (OPC): Independent Validation on a Large Prospective Cohort and a Secondary Analysis of NRG-HN002
316 - The Preliminary Analysis of Circulating Human Papillomavirus DNA in a Phase III Trial of Concurrent Chemoradiation (CRT) with Intensity Modulated Proton Therapy (IMPT) vs. IMRT in Oropharyngeal Squamo
1072 - Sequential 90Y Selective Internal Radiation Therapy (SIRT) and Stereotactic Body Radiation Therapy (SBRT) Using 90Y PET-Based Absorbed Dose Maps: Interim Analysis of a Phase I St
1073 - Comprehensive Geriatric Assessment Guided Radiotherapy in Older Patients with Locally Advanced Rectal Cancer - Results of a Multicenter Prospective Non-Operative Cohort Study
Location: Room 152
Presenter: Yuexin Yang, MD – Chinese Academy of Medical Sciences Cancer Hospital Shenzhen Hospital
4:20 PM - 4:25 PM ET
1074 - Long-Term Outcomes of Definitive Chemoradiation with Proton Therapy for Treatment of Carcinoma of the Anal Canal: Combined Analysis of Two Prospective Trials
Location: Room 152
Presenter: Grace Lee, MD – Harvard Radiation Oncology Program
4:25 PM - 4:30 PM ET
1075 - Patient Reported Outcomes after Chemoradiation with IMPT vs. IMRT for Patients with Anal Canal Squamous Cell Carcinoma
1083 - Outcome and Pattern of Failure Following Definitive High-Dose Radiotherapy for PrImary Vulvar CancEr: Interim Analysis of The DRIVE Multicenter Cohort Study
1086 - Outcomes of Radiotherapy in the First-Line Treatment of Recurrent/Metastatic Cervical Cancer: A Multicenter, Retrospective Study
Location: Room 204
Presenter: Peng Xie – Shandong Cancer Hospital and Institute
4:25 PM - 4:30 PM ET
1087 - A Retrospective Comparison of Acute Toxicities in Patients Receiving Pelvic Radiation for Newly Diagnosed Gynecologic Primaries with Intensity Modulated Proton Therapy and Volume Modulated Arc Therapy
Location: Room 204
Presenter: Matthew Brown, MD – University of Maryland Radiation Oncology
4:30 PM - 4:35 PM ET
1088 - The Evaluation of Anxiety and Pain Levels in Patients Receiving Brachytherapy: Turkish Society For Radiation Oncology Brachytherapy Group Study (Brg-001)
Location: Room 204
Presenter: Ferah Yildiz, MD – Hacettepe University Medical School
4:35 PM - 4:55 PM ET
Questions and Answers
Location: Room 204
4:55 PM - 5:00 PM ET
Closing
Location: Room 204
4:00 PM - 4:05 PM ET
Introduction
Location: Room 209
4:05 PM - 4:10 PM ET
1077 - Routine Physics Work Efficacy and Efficiency Improvement with Duty Shared Among Daily Physicist Group for a Multi Hospital Radiation Oncology Network
1079 - Automatic Large-Scale Prospective Monitoring and Blind Evaluation of the Performance of Commercial AI Auto-Segmentation in Routine Clinical Practice: Preliminary Results for a Cohort of Breast Cancer
1082 - Impact of Standardized Structure Templates on Violations for Radiation Plans Submitted to Co-Operative Group Clinical Trials
Location: Room 209
Presenter: Gobind Gill, MD – University of Alabama at Birmingham
4:35 PM - 4:55 PM ET
Questions and Answers
Location: Room 209
4:55 PM - 5:00 PM ET
Closing
Location: Room 209
5:15 PM - 5:25 PM ET
328 - Cellular Immune and Genomic Biomarkers in NRG-HN003, a Phase I Study Adding Pembrolizumab to Adjuvant Cisplatin and Radiation Therapy (CRT) in Pathologically High-Risk Head and Neck Cancer (HNSCC)
Location: Room 146
Presenter: Julie Bauman, MD – George Washington University Cancer Center
5:25 PM - 5:35 PM ET
329 - Metrics Derived from Architecture of Tumor-Infiltrating Lymphocytes are Associated with Overall Survival in HPV-Positive Oropharyngeal Squamous Cell Carcinoma Patients: Results from NRG/RTOG 0129 and
330 - Tumor Hypoxia on 18F-Fluoromisonidazole Positive Emission Tomography as a Predictor of Distant Metastasis-Free Survival after Chemoradiation for Head and Neck Squamous Cell Carcinoma: A Pooled Analysi
332 - Chromosomal Instability as a Prognostic Biomarker for Local Failure in Laryngeal Carcinoma Patients Treated with Definitive Radiation in NRG/RTOG 9512
1091 - Characterization of Focal Leptomeningeal Disease among Patients with Brain Metastases: A Novel Entity
Location: Room 151
Presenter: Nayan Lamba, MD – Harvard Radiation Oncology Program
5:35 PM - 5:40 PM ET
1092 - Pre-Operative vs. Post-Operative Fractionated Stereotactic Radiotherapy: A Single-Institution Analysis of 534 Resected Metastases
Location: Room 151
Presenter: Haley Perlow, MD – Case Western Reserve University/University Hospitals Cleveland Medical Center
5:40 PM - 5:45 PM ET
1093 - Maximum Tolerated Dose of Neoadjuvant Stereotactic Radiosurgery and Post-Treatment Immune Profiling for Metastatic Brain Tumors: Results of a Phase I Dose Escalation Trial
1094 - Multi-Center Phase I Study of Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor Brain Metastases (BM) or Leptomeningeal Metastases (LM) Harboring PI3K Pathway Mutations
1096 - Automated Segmentation of Pancreatic Tumor Microvasculature in High-Resolution Optical Coherence Tomography (OCT) Using Pre-Trained Large-Scale Supervised Networks for Early Evaluation of Radiation Th
1099 - The Novel Assessment of Stereotactic Body Radiotherapy (SBRT) for Cardiac Radioablation to the Cavotricuspid Isthmus by 13C Pyruvate Metabolic Imaging and Redox Reaction Imaging Using Dynamic Nuclear